Publicacións en colaboración con investigadores/as de Pfizer (United States) (6)

2023

  1. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

    Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487

2022

  1. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

2014

  1. Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies

    Arthritis and Rheumatology, Vol. 66, Núm. 4, pp. 940-949